(RTTNews) - CervoMed Inc. (CRVO) announced that initial biomarker results from its ongoing Phase 2a clinical trial of Neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA) have been accepted for a late-breaking oral presentation at the International